YARS1 and Alzheimer disease: Our study also provides a potential molecular explanation for high dose trans-RSV-mediated brain volume loss in AD patients21, worsening memory in schizophrenia22, and increased the CVD risk24, similar to high concentrations of trans-RSV that depletes TyrRS and exacerbates neurotoxic effects in our study.